HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.
Stocks · News reference
CervoMed Presents New Insights Into Neflamapimod's Treatment Effects In Dementia with Lewy Bodies At The Alzheimer's Association International Conference 2026
New analyses of Phase 2b clinical trial reinforce treatment effect of neflamapimod observed relative to placebo in "pure" DLB and support selection of 50 mg TID for planned Phase 3 study in DLBNeflamapimod
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — CervoMed Inc. (CRVO)
Filed: 2026-08-10 AccNo: 0001437749-26-026771 Size: 207 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Canaccord Genuity Maintains Buy on CervoMed, Lowers Price Target to $18
Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and lowers the price target from $27 to $18.
CervoMed Q2 EPS $(0.64) Misses $(0.60) Estimate
CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.60) by 6.67 percent. This is a 8.57 percent increase over losses of $(0.70) per share from the